The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new company holding its employees and other assets.

biopharmadive.com

Lilly pads cancer drug pipeline with Scorpion deal

Eli Lilly, one of the world's leading drug manufacturers, reached an agreement to acquire Scorpion Therapeutics cancer inhibitor program

Eli Lilly, una de las principales fabricantes de medicamentos del mundo, llegó a un acuerdo para adquirir programa de inhibidores de cáncer de Scorpion Therapeutics

Lilly acuerda compra del tratamiento contra cáncer de Scorpion por US$2.500 millones

larepublica.co

Bogotá

Bogota

Colombia

Lilly Agrees to Purchase Scorpion Cancer Treatment for $2.5 Billion

SAN FRANCISCO — Eli Lilly’s chief scientific officer said Monday that the company purchased a cancer drug from the startup Scorpion Therapeutics because Scorpion’s drug appeared better than similar molecules it had been working on itself.
“This is an example of a target that we’ve been working on…

BizToc

Eli Lilly scientific chief Skovronsky says Scorpion deal ‘checked all the boxes’

Eli Lilly, one of the world's leading drug manufacturers, reached a definitive agreement to purchase for up to $2.5 billion the Scorpion Therapeutics cancer inhibitor program.STX-478 is a selective PI3Kα inhibitor, a protein responsible for the growth of certain cancer cells.The innovative thing about treatment is that it specifically targets cancer cells with mutations in this protein, without affecting healthy cells.

Eli Lilly, una de las principales fabricantes de medicamentos del mundo, llegó a un acuerdo definitivo para adquirir por hasta 2,500 millones de dólares el programa de inhibidores de cáncer de Scorpion Therapeutics.STX-478 es un inhibidor selectivo de PI3Kα, una proteína responsable del crecimiento de ciertas células cancerosas. Lo innovador del tratamiento es que se dirige específicamente a las células cancerígenas con mutaciones en esta proteí…

Eli Lilly acuerda la compra del tratamiento contra el cáncer de Scorpion por 2,500 millones de dólares

El Economista

Eli Lilly agrees to buy Scorpion cancer treatment for $2.5 billion

With a projected revenue of USD 432.6 billion by 2032, the Oncology Cancer Drugs market is experiencing significant growth, driven by a CAGR of 9.43%. LONDON , ENGLAND, UNITED KINGDOM, January 15, 2025 /EINPresswire.com/ -- 𝚆𝙶𝚁 released the report titled "oncology cancer drugs Market have 2025-2034, Latest Industry Status and Outlook." This report provides a comprehensive analysis of the global oncology cancer drugs Market landscape, with a f…

kalkinemedia.com

Oncology Cancer Drugs Market Growth at 9. 43% CAGR, Targeting 432. 6 Billion USD by 2032 | Eli Lilly and Company

The deal, worth up to $2.5 billion, comes as Lilly broadens its pipeline beyond its wildly successful obesity and diabetes medicine.

Ad Fontes Media

All Sides

Media Bias/Fact Check

STAT

The Boston Globe

Boston

Suffolk County

Massachusetts

United States

Eli Lilly acquires cancer program from Scorpion Therapeutics in $2.5B deal

The acquisition will expand Lilly’s oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial STX-478 could potentially address 30-40% of people with hormone-positive breast cancer, building on Lilly’s advancements against this disease INDIANAPOLIS, IN and BOSTON, MA, USA I January 13, 2025 I Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutic…

pipelinereview

Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program - Pipelinereview

Eli Lilly and Company and Scorpion Therapeutics, a private biotechnology company developing small molecule precision oncology therapies, announced a definitive agreement for Lilly to acquire Scorpion’s PI3Kα inhibitor program STX-478. STX-478 is a once-daily oral, mutant-selective PI3Kα inhibitor currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumours.   STX-478 could represent the next generati…

Express Pharma

Eli Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program - Express Pharma

By Daniel Lee, Indianapolis Business Journal Eli Lilly and Co. announced Monday that it is buying Boston-based Scorpion Therapeutics and its targeted breast cancer treatment program in a deal worth up to $2.5 billion. The Indianapolis-based drugmaker will acquire Scorpion’s STX-478, a once-daily oral treatment in early trials for breast cancer and other advanced solid tumors. The therapy is designed to target PI3Ka gene mutations. “We look forwa…

dailyjournal.net

Lilly acquires Scorpion Therapeutics in deal worth up to $2.5B

American pharmaceutical company Eli Lilly announced on Monday that it intends to acquire Scorpion Therapeutics' experimental cancer therapy, STX-478, for up to $2.5 billion in cash, in order to expand its portfolio of oncology treatments, CNBC reports.

Compania farmaceutică americană Eli Lilly a anunţat luni că intenţionează să achiziţioneze terapia experimentală pentru cancer dezvoltată de Scorpion Therapeutics, STX-478, pentru o sumă de până la 2,5 miliarde de dolari în numerar, în scopul extinderii portofoliului său de tratamente oncologice, relatează CNBC.

Eli Lilly achiziţionează terapia experimentală pentru cancer a Scorpion Therapeutics, pentru până la 2,5 miliarde de dolari

News.ro

Eli Lilly to acquire experimental cancer therapy from Scorpion Therapeutics for up to $2.5 billion

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a breast cancer therapy being developed by Scorpion Therapeutics

Lilly pads cancer drug pipeline with Scorpion deal

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics